Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1Graft vs Host Disease 1

Interventions

pembrolizumab 1034Carboplatin 973Paclitaxel 942Gemcitabine 799Cisplatin 759Docetaxel 699Bevacizumab 637Nivolumab 520Pemetrexed 509Cyclophosphamide 476Capecitabine 475Fluorouracil 425Dexamethasone 410Rituximab 392Oxaliplatin 352Injections 349Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 252Ipilimumab 244Doxorubicin 242Lenalidomide 231Fulvestrant 226fludarabine 221durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × eritoran × Clear all
NCT00756912 2014-07-11

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Eisai Inc.

Phase 1 Terminated
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡